5 completed, 5 recruiting, 4 active not recruiting, 1 terminated. 15 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 5, Recruiting 5, Active not recruiting 4, Terminated 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Placebo IV: new trials by email Literature Review of Placebo IV trials Research Report on Placebo IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo Placebo IV, EB06 - Non-Segmental Vitiligo (NSV) | Phase 2 | Recruiting | Edesa Biotech Inc. | 80 | 2026-09-01 | 2026-10-27 |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) | Phase 2 | Recruiting | argenx | 40 | 2026-07-10 | 2026-11-04 |
| A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy ARGX-119 IV, Placebo IV - Spinal Muscular Atrophy (SMA) | Phase 2 | Recruiting | argenx | 60 | 2025-12-19 | 2026-10-08 |
| Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia SAD IV Dose 1 - 150mg ABS201 IV Single Dose, Placebo IV, ABS-201 SC Multiple Doses - Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female | Phase 1 / Phase 2 | Recruiting | Absci Pty Ltd. | 227 | 2025-12-03 | 2026-10-28 |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | argenx | 24 | 2025-10-20 | 2026-10-16 |
| A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis Empasiprubart IV, Placebo IV - Dermatomyositis, Myositis | Phase 2 | Active not recruiting | argenx | 3 | 2024-08-20 | 2026-11-04 |
| Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus SAR441344 IV, SAR441344 SC, Placebo IV - Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | Sanofi | 109 | 2021-11-10 | 2026-09-22 |
| Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis SAR441344 IV, placebo IV, SAR441344 SC - Multiple Sclerosis | Phase 2 | Active not recruiting | Sanofi | 129 | 2021-06-07 | 2026-09-28 |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Ramucirumab, Merestinib, Cisplatin - Biliary Tract Cancer, Metastatic Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 309 | 2016-05-19 | 2026-07-22 |
| To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease MEDI6012, Placebo SC, Placebo IV - Coronary Artery Disease | Phase 2 | Completed | MedImmune LLC | 48 | 2015-12-03 | 2018-03-19 |
| A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery CR845 IV 1 mcg/kg, CR845 IV 0.5 mcg/kg, Placebo IV - Post Abdominal Surgery Pain | Phase 2 / Phase 3 | Completed | Cara Therapeutics, Inc. | 451 | 2015-09-01 | 2019-05-31 |
| Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study GSK962040 50 mg, Metoclopramide 10 mg, Placebo NG - Gastroparesis | Phase 2 | Terminated | GlaxoSmithKline | 91 | 2014-04-04 | 2017-12-11 |
| Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc - Rheumatoid Arthritis | Phase 2 | Completed | UCB Pharma | 221 | 2010-11-01 | 2024-07-17 |
| To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate CDP6038, Placebo IV, Placebo SC - Arthritis, Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | UCB Pharma | 40 | 2009-10-01 | 2024-11-15 |
| A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg, Placebo SC - Crohn Disease | Phase 2 | Completed | Centocor, Inc. | 131 | 2004-04-01 | 2014-02-13 |
Arthritis, Rheumatoid (2) · Alopecia (1) · Arthritis (1) · Biliary Tract Neoplasms (1) · Coronary Artery Disease (1) · Critical Illness (1) · Crohn Disease (1) · Dermatomyositis (1) · Gastroparesis (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Muscular Atrophy, Spinal (1) · Myasthenia Gravis (1) · Myositis (1) · Neoplasm Metastasis (1)
argenx (4) · Sanofi (2) · UCB Pharma (2) · Absci Pty Ltd. (1) · Cara Therapeutics, Inc. (1) · Centocor, Inc. (1) · Edesa Biotech Inc. (1) · Eli Lilly and Company (1) · GlaxoSmithKline (1) · MedImmune LLC (1)
United States (12) · Spain (6) · Canada (5) · Australia (4) · Belgium (4) · Germany (4) · United Kingdom (4) · France (3) · Greece (3) · Italy (3) · Russia (3) · Turkey (Türkiye) (3) · Argentina (2) · Czechia (2) · Georgia (2)
PMID 18706417, PMID 24641941, PMID 30739254, PMID 34121413, PMID 34592180, PMID 38354138, PMID 39899371
2025 (3), 2023 (2), 2009 (1), 2015 (1)